REBECCA GRILLO: Open Payments
NPI 1093856833 · NORTH HAVEN, CT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,900 in 95 payments from 21 companies in 2025. Trend: 2023 $901 · 2024 $2,163 · 2025 $1,900
Food & beverage: $1,900
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 34 | $546 |
| AstraZeneca Pharmaceuticals LP | 9 | $268 |
| GlaxoSmithKline, LLC. | 11 | $215 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 8 | $137 |
| Lilly USA, LLC | 6 | $131 |
| Novo Nordisk Inc | 4 | $111 |
| Indivior Inc. | 3 | $90 |
| Merck Sharp & Dohme LLC | 3 | $61 |
| Amgen Inc. | 3 | $58 |
| Madrigal Pharmaceuticals | 2 | $55 |
Products named: VRAYLAR, BREZTRI, TRELEGY ELLIPTA, XIFAXAN, SUBLOCADE, Wegovy, MOUNJARO, AIRSUPRA.
Industry payments across CT — which companies pay providers there.
